Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial

RCT found a combination product of insulin glargine & lixisenatide was superior to premix insulin analog for HbA1c reduction in patients with suboptimally controlled basal insulin-treated type 2 diabetes (-1.3% vs -1.1%, difference -0.2%, 97.5%CI -0.4 to -0.1%).

SPS commentary:

In UK, insulin glargine and lixisenatide under brand name Suliqua, is licensed for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.

Diabetes Care